ArticleMolecular and clinical oncology2019
Non-specific elevation of serum Mac-2 binding protein glycosylation isomer levels in patients with biliary disease.
Article in Molecular and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to clarify the clinical significance of a novel fibrotic marker, serum Mac-2 binding protein glycosylation isomer (M2BPGi), in non-cirrhotic patients with biliary diseases. Associations between the serum levels of M2BPGi and clinical features (including background disease and laboratory data) were analyzed. A total of 78 patients with biliary disease (32 with biliary cancer and 46 with benign disease) were evaluated, and their clinical features (age, sex and biliary stricture status), serum level of M2BPGi and other serum laboratory data [aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyltranspeptidase (γ-GTP), alkaline phosphatase (ALP), total bilirubin (TB), direct bilirubin (DB), c-reactive protein (CRP), carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9)] were compared. In addition, correlations between the serum level of M2BPGi and other laboratory data were also evaluated. The median serum M2BPGi was increased in cases of biliary tumor [cut-off index (COI), 1.91] compared with cases of benign disease (COI, 0.73; P<0.0001). All biliary cancer cases presented with biliary strictures, and 5 patients had liver metastases. Cases with liver metastases exhibited higher M2BPGi levels compared with cases without liver metastases (COI, 3.75 vs. 1.53; P=0.008). The level of M2BPGi was correlated with levels of AST, ALT, γ-GTP, ALP, TB, DB, CRP, CEA and CA19-9. In conclusion, the serum M2BPGi level could be non-specifically elevated, particularly in non-cirrhotic patients with biliary stricture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.